Helicase-like transcription factor: a new marker of well-differentiated thyroid cancers

BMC Cancer

Vanessa Arcolia⁶  Paula Paci⁷  Ludovic Dhont⁴  Gilbert Chantrain¹  Nicolas Sirtaine³  Christine Decaestecker²  Myriam Remmelink⁵  Alexandra Belayew⁴  Sven Saussez⁶ 

[1] Department of Oto-Rhino-Laryngology, CHU Saint-Pierre, Free University of Brussels, Brussels, Belgium

[2] Laboratory of Image, Signal Processing and Acoustics (LISA), Ecole Polytechnique de Bruxelles, Free University of Brussels, Brussels, Belgium

[3] Department of Pathology, Institute Bordet, Free University of Brussels, Brussels, Belgium

[4] Laboratory of Molecular Biology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons, 7000 Mons, Belgium

[5] Department of Pathology, Hospital Erasme, Free University of Brussels, Brussels, Belgium

[6] Laboratory of Anatomy and Cell Biology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons, 7000 Mons, Belgium

[7] Present address: Laboratory of Neurosciences, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons, 7000 Mons, Belgium

关键词: Cancer;    Thyroid lesions;    Tumor suppressor;    Diagnosis;    HLTF;    Biomarker;   

Others  :  856926
DOI  :  10.1186/1471-2407-14-492

 received in 2014-01-07, accepted in 2014-07-01,  发布年份 2014

【 摘 要 】

Background

The preoperative characterization of thyroid nodules is a challenge for the clinicians. Fine-needle aspiration (FNA) is the commonly used pre-operative technique for diagnosis of malignant thyroid tumor. However, many benign lesions, with indeterminate diagnosis following FNA, are referred to surgery. There is an urgent need to identify biomarkers that could be used with the FNA to distinguish benign thyroid nodules from malignant tumors. The purpose of the study is to examine the level of expression of the helicase-like transcription factor (HLTF) in relation to neoplastic progression of thyroid carcinomas.

Methods

The presence of HLTF was investigated using quantitative and semi-quantitative immunohistochemistry in a series of 149 thyroid lesion specimens. Our first clinical series was composed of 80 patients, including 20 patients presenting thyroid adenoma, 40 patients presenting thyroid papillary carcinoma, 12 patients presenting thyroid follicular carcinoma and 8 patients presenting anaplastic carcinoma. These specimens were assessed quantitatively using computer assisted microscopy. Our initial results were validated on a second clinical series composed of 40 benign thyroid lesions and 29 malignant thyroid lesions using a semi-quantitative approach. Finally, the HLTF protein expression was investigated by Western blotting in four thyroid cancer cell lines.

Results

The decrease of HLTF staining was statistically significant during thyroid tumor progression in terms of both the percentage of mean optical density (MOD), which corresponds to the mean staining intensity (Kruskall-Wallis: p < 0.0005), and the labelling index (LI), which corresponds to the percentage of immunopositive cells (Kruskall-Wallis: p < 10⁻⁶). Adenomas presented very pronounced nuclear HLTF immunostaining, whereas papillary carcinomas exhibited HLTF only in the cytoplasm. The number of HLTF positive nuclei was clearly higher in the adenomas group (30%) than in the papillary carcinomas group (5%).

The 115-kDa full size HLTF protein was immunodetected in four studied thyroid cancer cell lines. Moreover, three truncated HLTF forms (95-kDa, 80-kDa and 70-kDa) were also found in these tumor cells.

Conclusions

This study reveals an association between HLTF expression level and thyroid neoplastic progression. Nuclear HLTF immunostaining could be used with FNA in an attempt to better distinguish benign thyroid nodules from malignant tumors.

【 授权许可】

   
2014 Arcolia et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Ding H, Descheemaeker K, Marynen P, Nelles L, Carvalho T, Carmo-Fonseca M, Collen D, Belayew A: Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. DNA Cell Biol 1996, 15:429-442.
• [3]Debauve G, Capouillez A, Belayew A, Saussez S: The helicase-like transcription factor and its implication in cancer progression. Cell Mol Life Sci 2008, 65:591-604.
• [4]Blastyak A, Hajdu I, Unk I, Haracska L: Role of double-stranded DNA translocase activity of human HLTF in replication of damaged DNA. Mol Cell Biol 2010, 30:684-693.
• [5]Motegi A, Sood R, Moinova H, Markowitz SD, Liu PP, Myung K: Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J Cell Biol 2006, 175:703-708.
• [6]Unk I, Hajdu I, Fatyol K, Hurwitz J, Yoon JH, Prakash L, Prakash S, Haracska L: Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc Natl Acad Sci U S A 2008, 105:3768-3773.
• [7]Tian F, Sharma S, Zou J, Lin SY, Wang B, Rezvani K, Wang H, Parvin JD, Ludwig T, Canman CE, Zhang D: BRCA1 promotes the ubiquitination of PCNA and recruitment of translesion polymerases in response to replication blockade. Proc Natl Acad Sci U S A 2013, 110:13558-13563.
• [8]Burkovics P, Sebesta M, Balogh D, Haracska L, Krejci L: Strand invasion by HLTF as a mechanism for template switch in fork rescue. 2013. [Epub ahead of print]
• [9]Helmer RA, Foreman O, Dertien JS, Panchoo M, Bhakta SM, Chilton BS: Role of helicase-like transcription factor (hltf) in the G2/m transition and apoptosis in brain. PLoS One 2013, 8:e66799.
• [10]Helmer RA, Martínez-Zaguilán R, Dertien JS, Fulford C, Foreman O, Peiris V, Chilton BS: Helicase-like transcription factor (hltf) regulates g2/m transition, wt1/gata4/hif-1a cardiac transcription networks, and collagen biogenesis. PLoS One 2013, 8:e80461.
• [11]Bai AH, Tong JH, To KF, Chan MW, Man EP, Lo KW, Lee JF, Sung JJ, Leung WK: Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int J Cancer 2004, 112:846-853.
• [12]Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, Herman JG: CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 2005, 26:1152-1156.
• [13]Hibi K, Nakayama H, Kanyama Y, Kodera Y, Ito K, Akiyama S, Nakao A: Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer 2003, 104:433-436.
• [14]Hibi K, Nakao A: Lymph node metastasis is infrequent in patients with highlymethylated colorectal cancer. Anticancer Res 2006, 26:55-58.
• [15]Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, Stain S, Chapman WC, Washington MK, Willis J, Markowitz SD, Grady WM: CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 2006, 45:781-789.
• [16]Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Lee JF, Sung JJ: Detection of epigenetic changes in fecal-DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem 2004, 50:2179-2182.
• [17]Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ: Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005, 100:2274-2279.
• [18]Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY, Sung JJ: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007, 102:1070-1076.
• [19]Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz : HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A 2009, 99:4562-4567.
• [20]Leung WK, Yu J, Bai AH, Chan MW, Chan KK, To KF, Chan FK, Ng EK, Chung SC, Sung JJ: Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer. Mol Carcinog 2003, 37:91-97.
• [21]Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, Nakayama H, Yasui W: Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006, 106:1250-1259.
• [22]Fukuoka T, Hibi K, Nakao A: Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. Anticancer Res 2006, 26:3333-3335.
• [23]Kang S, Kim J, Kim HB, Shim JW, Nam E, Kim SH, Ahn HJ, Choi YP, Ding B, Song K, Cho NH: Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. Diagn Mol Pathol 2006, 15:74-82.
• [24]Sandhu S, Wu X, Nabi Z, Rastegar M, Kung S, Mai S, Ding H: Loss of HLTF function promotes intestinal carcinogenesis. Mol Cancer 2012, 11:18.
• [25]Debauve G, Nonclercq D, Ribaucour F, Wiedig M, Gerbaux C, Leo O, Laurent G, Journé F, Belayew A, Toubeau G: Early expression of the Helicase- Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis. Mol Cancer 2006, 5:23.
• [26]Capouillez A, Debauve G, Decaestecker C, Filleul O, Chevalier D, Mortuaire G, Coppée F, Leroy X, Belayew A, Saussez S: The helicase-like transcription factor is a strong predictor of recurrence in hypopharyngeal but not in laryngeal squamous cell carcinomas. Histopathology 2009, 55:77-90.
• [27]Capouillez A, Noël JC, Arafa M, Arcolia V, Mouallif M, Guenin S, Delvenne P, Belayew A, Saussez S: Expression of the helicase-like transcription factor and its variants during carcinogenesis of the uterine cervix: implications for tumour progression. Histopathology 2011, 58:984-988.
• [28]van Staveren WC, Solís DW, Delys L, Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V, Maenhaut C: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res 2007, 67:8113-8120.
• [29]Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A, van Staveren WC, Maenhaut C: Thyroid cancer cell lines: an overview. Front Endocrinol (Lausanne) 2012, 3:133.